CA2394079C - Weight promoting composition, method and product - Google Patents
Weight promoting composition, method and product Download PDFInfo
- Publication number
- CA2394079C CA2394079C CA002394079A CA2394079A CA2394079C CA 2394079 C CA2394079 C CA 2394079C CA 002394079 A CA002394079 A CA 002394079A CA 2394079 A CA2394079 A CA 2394079A CA 2394079 C CA2394079 C CA 2394079C
- Authority
- CA
- Canada
- Prior art keywords
- pregnane
- administration
- per unit
- weight
- unit dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 39
- 230000001737 promoting effect Effects 0.000 title claims description 33
- 238000000034 method Methods 0.000 title description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 10
- 229910006069 SO3H Inorganic materials 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims abstract description 7
- 210000001121 vomeronasal organ Anatomy 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims abstract description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 35
- JWMFYGXQPXQEEM-NUNROCCHSA-N 5β-pregnane Chemical compound C([C@H]1CC2)CCC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](CC)[C@@]2(C)CC1 JWMFYGXQPXQEEM-NUNROCCHSA-N 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 18
- 208000030814 Eating disease Diseases 0.000 claims description 16
- 235000014632 disordered eating Nutrition 0.000 claims description 16
- 230000009885 systemic effect Effects 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 12
- 206010002653 Anosmia Diseases 0.000 claims description 12
- 208000009233 Morning Sickness Diseases 0.000 claims description 12
- 208000034850 Vomiting in pregnancy Diseases 0.000 claims description 12
- 235000019558 anosmia Nutrition 0.000 claims description 12
- 208000001132 Osteoporosis Diseases 0.000 claims description 11
- 230000004580 weight loss Effects 0.000 claims description 10
- 208000030507 AIDS Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 7
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 230000001815 facial effect Effects 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003128 pregnanes Chemical class 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 55
- 239000004480 active ingredient Substances 0.000 description 27
- 238000013459 approach Methods 0.000 description 26
- 238000011282 treatment Methods 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 21
- 235000019789 appetite Nutrition 0.000 description 19
- 230000036528 appetite Effects 0.000 description 18
- 230000004044 response Effects 0.000 description 17
- 230000008901 benefit Effects 0.000 description 14
- 235000005686 eating Nutrition 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 230000035611 feeding Effects 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 12
- -1 METHOD Substances 0.000 description 11
- 230000004584 weight gain Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 150000003431 steroids Chemical class 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000035935 pregnancy Effects 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000001010 compromised effect Effects 0.000 description 7
- 238000001647 drug administration Methods 0.000 description 7
- 235000012631 food intake Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 208000016261 weight loss Diseases 0.000 description 6
- 206010006895 Cachexia Diseases 0.000 description 5
- 102000006771 Gonadotropins Human genes 0.000 description 5
- 108010086677 Gonadotropins Proteins 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000002622 gonadotropin Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000000541 pulsatile effect Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 230000033764 rhythmic process Effects 0.000 description 4
- 230000000276 sedentary effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 206010016165 failure to thrive Diseases 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 235000003642 hunger Nutrition 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010048828 underweight Diseases 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010049238 Food aversion Diseases 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010048636 Self-induced vomiting Diseases 0.000 description 2
- 208000037063 Thinness Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004597 appetite gain Effects 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000009223 counseling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 206010021654 increased appetite Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 208000020442 loss of weight Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002294 pubertal effect Effects 0.000 description 2
- 230000001739 rebound effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000027559 Appetite disease Diseases 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010050366 Fear of eating Diseases 0.000 description 1
- 208000018460 Feeding disease Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- 206010020028 Hiatus hernia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000006203 ethylation Effects 0.000 description 1
- 238000006200 ethylation reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 150000002874 norpregnenes Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 210000001696 pelvic girdle Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 150000003130 pregnenes Chemical class 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000036391 respiratory frequency Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000022676 rumination Effects 0.000 description 1
- 208000015212 rumination disease Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/475,328 | 1999-12-30 | ||
| US09/475,328 US6555531B1 (en) | 1999-12-30 | 1999-12-30 | Weight promoting composition, method, and product |
| PCT/US2000/035573 WO2001049280A2 (en) | 1999-12-30 | 2000-12-28 | Weight promoting composition, method, and product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2394079A1 CA2394079A1 (en) | 2001-07-12 |
| CA2394079C true CA2394079C (en) | 2009-09-29 |
Family
ID=23887094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002394079A Expired - Fee Related CA2394079C (en) | 1999-12-30 | 2000-12-28 | Weight promoting composition, method and product |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6555531B1 (enExample) |
| EP (1) | EP1244458B1 (enExample) |
| JP (1) | JP2003519179A (enExample) |
| AR (1) | AR027136A1 (enExample) |
| AT (1) | ATE374613T1 (enExample) |
| AU (1) | AU2463301A (enExample) |
| CA (1) | CA2394079C (enExample) |
| DE (1) | DE60036640T2 (enExample) |
| ES (1) | ES2292495T3 (enExample) |
| MX (1) | MXPA02006568A (enExample) |
| WO (1) | WO2001049280A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2008434A3 (cs) * | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3917831A (en) * | 1972-03-20 | 1975-11-04 | Richardson Merrell Inc | 3-Keto-7 {60 ,{62 -loweralkyl-{66 {0 5-steroids |
| US3946052A (en) * | 1975-06-16 | 1976-03-23 | Stanford Research Institute | 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity |
| US6066627A (en) * | 1994-08-04 | 2000-05-23 | Pherin Corporation | Steroids as neurochemical initiators of change in human blood levels of LH |
| US5792757A (en) * | 1994-08-04 | 1998-08-11 | Pherin Pharmaceuticals | 19-nor-pregnane steroids as neurochemical initiators of change in human hypothalamic function |
| BE1010266A4 (nl) | 1996-04-15 | 1998-04-07 | Option International | Aanpassingseenheid voor datatransmissie tussen een mobiele telefoon en een gegevensterminal. |
| PL331357A1 (en) | 1996-07-23 | 1999-07-05 | Pherin Pharmaceuticals | Steroids as neurochemical vno stimulators for soothing the symptoms of premenstrual tension and anxiety |
-
1999
- 1999-12-30 US US09/475,328 patent/US6555531B1/en not_active Expired - Fee Related
-
2000
- 2000-12-28 AU AU24633/01A patent/AU2463301A/en not_active Abandoned
- 2000-12-28 MX MXPA02006568A patent/MXPA02006568A/es active IP Right Grant
- 2000-12-28 DE DE60036640T patent/DE60036640T2/de not_active Expired - Lifetime
- 2000-12-28 CA CA002394079A patent/CA2394079C/en not_active Expired - Fee Related
- 2000-12-28 AT AT00988423T patent/ATE374613T1/de not_active IP Right Cessation
- 2000-12-28 AR ARP000106993A patent/AR027136A1/es unknown
- 2000-12-28 ES ES00988423T patent/ES2292495T3/es not_active Expired - Lifetime
- 2000-12-28 WO PCT/US2000/035573 patent/WO2001049280A2/en not_active Ceased
- 2000-12-28 EP EP00988423A patent/EP1244458B1/en not_active Expired - Lifetime
- 2000-12-28 JP JP2001549648A patent/JP2003519179A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE374613T1 (de) | 2007-10-15 |
| EP1244458A2 (en) | 2002-10-02 |
| WO2001049280A2 (en) | 2001-07-12 |
| EP1244458B1 (en) | 2007-10-03 |
| AU2463301A (en) | 2001-07-16 |
| JP2003519179A (ja) | 2003-06-17 |
| DE60036640D1 (de) | 2007-11-15 |
| AR027136A1 (es) | 2003-03-12 |
| DE60036640T2 (de) | 2008-07-03 |
| WO2001049280A3 (en) | 2002-05-02 |
| CA2394079A1 (en) | 2001-07-12 |
| ES2292495T3 (es) | 2008-03-16 |
| MXPA02006568A (es) | 2003-10-15 |
| US6555531B1 (en) | 2003-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stamp et al. | Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs | |
| TWI784261B (zh) | 神經活性類固醇，其組合物及其用途 | |
| TWI336255B (en) | Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiqinone and a bronchodilating agent | |
| Bianchi et al. | Endocrine aspects of Duchenne muscular dystrophy | |
| Pekkarinen et al. | Sleep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors | |
| US10975116B2 (en) | Methods of treating and preventing gastrointestinal motility disorders using aminosterols | |
| US20220125803A1 (en) | Methods for the treatment of perimenopause and menopause | |
| JP3385583B2 (ja) | テストステロンの濃度を上昇させる薬剤 | |
| TW200410682A (en) | Treatment of anorexia nervosa (an) and bulimia | |
| ES2814951T3 (es) | Compuestos y sus efectos sobre el control del apetito y la sensibilidad a la insulina | |
| US6482858B1 (en) | (−)-hydroxycitric acid for wound healing and immunomodulation | |
| Koch | The biochemistry and physiological significance of the male sex hormones | |
| CA2394079C (en) | Weight promoting composition, method and product | |
| US20180055848A1 (en) | Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia | |
| US11766458B2 (en) | Method and a dietary composition on regulation, treatment, and prevention of obesity | |
| Ogura et al. | Effects of mats with" A Distinctive 4-Layer 3-Dimensional Structure" on sleep quality and menpause: An open-label study | |
| JP2616845B2 (ja) | システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤 | |
| Janney | III. STUDIES IN THYROID THERAPY: THE EFFECTS OF THE THYROID HORMONE AS DETERMINED BY A CLINICAL METABOLIC AND DIETETIC INVESTIGATION. NEW POINTS OF VIEW ON THYROID FUNCTION IN HEALTH AND DISEASE | |
| Ede et al. | Cireadian rhythm of therapeutie effectiveness of oxymetholone in paraplegie patients | |
| JPS63267722A (ja) | 抗肥満症剤 | |
| Miller et al. | The Life Extension Revolution: The New Science of Growing Older Without Aging | |
| TWI228992B (en) | Treatment of subnormal bone mineral density | |
| WO2025189151A1 (en) | Methods and compositions for treating disorders associated with low c-peptide | |
| US20250064802A1 (en) | Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases | |
| EP1964558A1 (en) | Pharmaceutical compositions containing intestinal lipase inhibiting substances combined with a chromium dinicotinate o-coordinated complex for use in the treatment and control of obesity and overweight |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20131230 |